There was an observed trend toward an increased DFS event rate beyond 36 months compared with the previous 36 months in the osimertinib group; however, the benefit of osimertinib treatment is clearly maintained as the curves remain separated beyond the 3-year treatment period.
← all excerpts
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
1
—
—